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Conflicting reports exist as to whether sickle cell trait is a risk
factor for the progression of nephropathy. In order to
determine whether African Americans with sickle cell trait are
at increased risk for kidney disease, we assessed the genetic
association between sickle cell trait and end-stage renal
disease (ESRD). Hemoglobin S, non-muscle myosin heavy
chain 9 (MYH9), and apolipoprotein L1 (APOL1) risk variants
were genotyped in 3258 unrelated African Americans: 1085
with non-diabetic ESRD, 996 with type 2 diabetes-associated
ESRD, and 1177 controls. Since APOL1 is strongly associated
with ESRD in African Americans, interactions between APOL1
and MYH9 risk variants and hemoglobin S were assessed
using case-only and case-control centered two-way logistic
regression interaction analyses. The sickle cell trait genotype
frequencies were 8.7% in non-diabetic ESRD, 7.1% in type
2 diabetes-ESRD, and 7.2% in controls. There was no age-,
gender-, and admixture-adjusted significance for sickle cell
trait association with non-diabetic ESRD (odds ratio 1.16);
type 2 diabetes-ESRD (odds ratio 1.01); or all-cause ESRD
(combined non-diabetic and type 2 diabetic-ESRD patients
compared to the controls; odds ratio 1.05) in dominant
models. In addition, no evidence of APOL1 or MYH9
interactions with sickle cell trait was detected. Hence, sickle
cell trait is not associated with diabetic or
non-diabetic ESRD in a large sample of African Americans.
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Individuals homozygous for the sickle (S) variant of
hemoglobin (Hb) A develop sickle cell disease, manifested
by anemia, recurrent pain crises, chronic kidney disease,
stroke, vascular occlusion, pulmonary disease, infectious
complications, and premature mortality.1 Renal manifesta-
tions in sickle cell disease may include loss of urinary
concentrating ability, papillary necrosis, glomerular lesions,
including focal segmental glomerulosclerosis (FSGS), inter-
stitial scarring, and iron deposition.2 Sickle cell trait has been
associated with papillary necrosis, hematuria, and urinary
concentrating defects.3 There have been conflicting reports as
to whether sickle cell trait is a risk factor for the development
of diabetic nephropathy.4–6 A recent report described a high
prevalence of sickle cell trait (heterozygous carriers; HbAS)
among African American end-stage renal disease (ESRD)
patients, suggesting an increased risk for individuals with
HbAS.7 Replication analyses in larger samples have yet to be
performed.
The HbAS genotype is present in approximately 7–9% of
African Americans, with higher frequencies in younger
individuals.8,9 HbS was selected for in Africa because of the
protection it affords from malarial infection, a scenario
similar to the protection from trypanosomal infection
provided by heterozygosity for apolipoprotein L1 (APOL1)
nephropathy risk variants (G1: non-synonymous coding
variant 342G:384M and G2: 6 bp deletion).10,11 Whereas
APOL1 contributes to nephropathy risk in an autosomal
recessive inheritance pattern, HbS reportedly had a dominant
effect on risk,7 with sickle cell trait being associated
with ESRD.
We tested for a genetic association between the single-
nucleotide polymorphism encoding HbS and ESRD in
African Americans residing in the southeastern United States
to determine whether the HbAS genotype was associated
with commonly reported etiologies of ESRD. Cases with
ESRD attributed to type 2 diabetes mellitus (T2D) and
non-diabetes mellitus (non-DM) causes, predominantly
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‘hypertension-attributed’ and glomerular disease associated,
were evaluated. In addition, relationships between APOL1
G1/G2 nephropathy risk variants and non-muscle myosin
heavy chain 9 gene (MYH9) risk variants (E1 risk haplo-
type)12–14 and HbS were assessed to determine whether
interactions between these genes were present.
RESULTS
Analyses were performed in 1085 unrelated African American
cases with nondiabetic etiologies of ESRD, 996 cases with
T2D–ESRD, and 1177 non-nephropathy controls (413 with
T2D). Table 1 contains demographic data from these 3258
individuals. Although controls were younger than ESRD
cases, they were older than the mean age at onset of T2D and
ESRD in the T2D–ESRD and non-DM ESRD cases,
respectively. Relative to the non-nephropathy controls, ESRD
cases had significantly higher percentages of African ancestry
(Table 1; P-value¼ 8.8 108). Individual African ancestry
proportion data were used as covariates in the program
SNPGWA version 4.0 (http://www.phs.wfubmc.edu/public/
bios/gene/downloads.cfm) to calculate genotypic association.
Table 2 displays HbAS genotype frequencies and Hardy–
Weinberg equilibrium results in the cases and controls. HbS
met Hardy–Weinberg equilibrium expectations in all groups
with a genotype frequency of 7.2% in controls, 8.7% in non-
DM ESRD cases, and 7.1% in T2D–ESRD cases. Table 2
reveals the African ancestry-adjusted association results for
HbS in non-DM ESRD cases, T2D–ESRD cases, and all-cause
(combined) ESRD cases, relative to non-nephropathy con-
trols. Significant evidence of association was not detected in
age, gender, and ancestry-adjusted analyses in cases with non-
DM ESRD (odds ratio (OR) 1.16; 95% confidence interval
(CI) 0.85–1.60; P¼ 0.34, dominant model), cases with
T2D–ESRD (OR 1.01; 95% CI 0.70–1.50; P¼ 0.96, dominant
model), or all-cause (combined) ESRD cases (OR 1.05; 95%
CI 0.79–1.40; P¼ 0.74, dominant model). Additional analyses
were performed by comparing the 1085 non-DM ESRD cases
with the 704 nondiabetic controls and the 996 T2D–ESRD
cases with the 413 T2D controls, and no evidence of
association with HbAS was detected (data not shown). When
including diabetes duration as a covariate in the model,
results were unchanged and HbAS was not associated with
T2D–ESRD (OR 1.13; 95% CI 0.68–1.67; P¼ 0.63).
Age, gender, and African ancestry-adjusted APOL1
association testing revealed an OR¼ 4.45 for association in
all ESRD cases (recessive model, 95% CI 3.60–5.49;
P¼ 9.24E44). Table 3 contains the results of interaction
analyses between HbAS and APOL1, and HbAS with MYH9
nephropathy risk variants employing both the powerful case-
only method, as well as the case–control two-way interaction
method. Because of low counts of HbS homozygotes, only
the dominant model had sufficient power for analysis. As
shown, there was no interaction between HbS and the MYH9
E1 risk haplotype or APOL1 G1 and G2 alleles.
DISCUSSION
The current report tested for genetic association between
sickle cell trait and common complex forms of ESRD in
African Americans. No evidence of association between
HbAS and either diabetic or nondiabetic etiologies of ESRD
was detected in this large sample of African Americans from
the southeastern United States. In addition, no evidence of an
interaction was seen between chromosome 22q nephropathy
risk variants in APOL1 or MYH9 and HbS. Patients with
sickle cell disease are known to develop renal abnormalities,
including risk for ESRD requiring renal replacement therapy.
Our results stand in contrast to a series of 188 patients with
ESRD reported by Derebail et al.7 In that series, almost
15% of ESRD cases had sickle cell trait as determined by
high-performance liquid chromatography. We performed
Table 1 | Demographic data in ESRD cases and non-nephropathy controls
Group N Female (%)
Mean±s.d.,
age (years)
Mean±s.d.,
BMI (kg/m2)
African
ancestry (%)
Mean±s.d., age
at ESRD (years)
Mean±s.d.,
age at T2D (years)
Non-DM ESRD cases 1085 44.3 53.9 (±14.6) 27.1 (±6.9) 79.5 (±10.3) 48.4 (±15.5) NA
T2D ESRD cases 996 60.0 61.6 (±10.4) 29.8 (±7.2) 78.7 (±11.4) 58.0 (±11.0) 41.5 (±12.4)
Non-nephropathy controls 1177 57.1 51.9 (±11.2) 32.1 (±13.1) 76.9 (±11.2) NA 45.7 (±10.1)a
Abbreviations: BMI, body mass index; DM, diabetes mellitus; ESRD, end-stage renal disease; NA, not applicable; T2D, type 2 diabetes mellitus.
aSubset of 413 controls with T2D.
Mean (s.d.) DM duration: 19.9 (10.7) years in T2D ESRD cases; 9.4 (7.9) years in non-nephropathy controls with T2D.
Table 2 | Genotypic association for HbS in ESRD cases with controls, adjusted for admixture, age, and gender
Group
Sample
size
HbAS genotype
frequency
HWE
controls
HWE
cases
P-value,
dominant OR (CI)
P-value,
additive OR (CI)
Non-DM ESRD 1085 0.087 0.619 0.406 0.3446 1.16 (0.85–1.6) 0.3402 1.18 (0.86–1.6)
T2D–ESRD 996 0.071 0.619 0.237 0.9617 1.01 (0.70–1.5) 0.9945 1.00 (0.70–1.4)
Combined all-cause ESRD 2081 0.079 0.619 0.171 0.7398 1.05 (0.79–1.4) 0.7436 1.05 (0.79–1.4)
Controls 1177 0.072 0.619 NA NA NA NA NA
Abbreviations: CI, 95% confidence interval; DM, diabetes mellitus; HbS, hemoglobin S; HbAS, sickle cell trait (heterozygous carriers); HWE, Hardy–Weinberg equilibrium; ESRD,
end-stage renal disease; NA, not applicable; OR, odds ratio; T2D, type 2 diabetes mellitus.
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direct genotyping in 2081 African Americans with ESRD. In
addition, interaction analyses were performed in this report
as chromosome 22q nephropathy risk variants predispose to
FSGS and focal global glomerulosclerosis in African Amer-
icans, lesions that are reported to occur in higher frequency
in patients with sickle cell disease.2 FSGS and focal
global glomerulosclerosis are now known to comprise the
vast majority of cases with non-DM ESRD in African
Americans.10,11,15
Strengths of the current report include the large sample
size, direct genotyping for HbS, and adjustment for overall
percentage of African ancestry, age, and gender. Moreover,
potential gene–gene interactions were assessed between HbS
and powerful renal disease polymorphisms in the APOL1 and
MYH9 genes. Individuals with HbAS genotypes have a
normal lifespan and are typically unaffected unless exposed
to low oxygen tension (high altitude) or high oxygen
demand. APOL1 and HbS both appear to have been selected
for in Africa on the basis of the protection they afford from
malaria and trypanosomal infection, respectively. However,
this analysis suggests that APOL1 and HbS both appear to be
associated with susceptibility to nephropathy in autosomal
recessive patterns, with no evidence of risk for nephropathy
in individuals heterozygous for risk variants (e.g., those with
sickle cell trait). Additional evidence from our group
supports the lack of an effect of sickle cell trait on
development of subclinical nephropathy in African Amer-
icans with diabetes mellitus.5 The cohort studied by Bleyer
et al.5 was limited to individuals with diabetes mellitus who
underwent determinations of estimated glomerular filtration
rates with simultaneous glycated hemoglobin testing during
outpatient clinic visits at Wake Forest Baptist Medical Center;
they were not enriched for ESRD. None of those individuals
were cases or controls in this report. Therefore, the current
results in cases with severe nephropathy (ESRD) are
consistent with those in subclinical nephropathy.
One must be careful to evaluate for any potential bias that
could occur and affect the study results. The cases were
recruited from dialysis centers throughout the southeastern
United States. A bias would be whether patients with sickle
cell trait preferentially underwent kidney transplantation or
whether individuals with sickle cell trait would be less likely
to participate in our study. It is interesting to note that many
individuals do not realize that they have sickle cell trait,16 and
testing for sickle cell trait is not routinely done in ESRD
patients. This would reduce the chance of bias. The
prevalence of sickle cell trait in the control population was
similar in our study and that of Derebail et al.7 Controls in
their report were derived from North Carolina live-birth
screenings for African Americans. The North Carolina State
Laboratory provided de-identified results for all live births
identified as African American for counties in which
University of North Carolina dialysis populations were based.
However, the prevalence of sickle cell trait was 15% in their
ESRD population compared with 8% in the current study
population. Although a different methodology was used to
determine the presence of sickle cell trait, this is unlikely to
have led to the differences in our findings. The present study
was much larger and encompassed a larger geographical area.
A potential study limitation is the possibility that small
numbers of controls with chronic kidney disease could have
been included; this would reduce the likelihood of detecting
association (although no trend was observed). Shorter T2D
durations in diabetic controls relative to T2D–ESRD cases
could also influence results, although adjusting for diabetes
duration did not change the results. It is difficult to identify
large numbers of African Americans with long durations of
diabetes lacking microalbuminuria because of their high
prevalence of nephropathy. In addition, subjects with DM
may develop progressive chronic kidney disease in the
absence of proteinuria. Finally, although logistic regression
does not address the possibility that sickle trait may affect
nephropathy progression rates, we feel that these data and the
report by Bleyer et al.5 make this less likely.
Association studies with multivariable adjustment may
miss differences that can be revealed with stratified analyses.
Although stratification provides the strongest protection
against confounding, it can also reduce power. We compared
the distribution of the two continuous covariates used in
these analyses by sickle trait status. The mean (s.d.) of age
and admixture was 56.8 years (13.9) and 0.80% (0.1) in the
sickle trait group and 55.7 years (12.9) and 0.78% (0.1) in
Table 3 | HbS–chromosome 22 nephropathy variant interaction analyses
Analysis type Non-DM ESRD T2D-ESRD All-cause ESRD
MYH9–E1 interaction P-value (N) P-value (N) P-value (N)
Case only 0.99 (case, N=1007) 0.23 (case, N=938) 0.39 (case, N=1945)
Case–control two-way interaction 0.46 (case, N=1007;
control, N=1098)
0.36 (case, N=938;
control, N=1098)
0.92 (case, N=1945;
control, N=1098)
APOL1–G1/G2 interaction
Case only 0.82 (case, N=1024) 0.28 (case, N=968) 0.30 (case, N=1992)
Case–control two-way interaction 0.1 (case, N=1024;
control, N=1089)
0.68 (case, N=968;
control, N=1089)
0.25 (case, N=1992;
control, N=1089)
Abbreviations: APOL1, apolipoprotein L1; DM, diabetes mellitus; ESRD, end-stage renal disease; HbS, hemoglobin S; MYH9, non-muscle myosin heavy chain 9; SNP, single-
nucleotide polymorphism; T2D, type 2 diabetes mellitus.
Case-only association and case–control centered two-way interaction tests were conducted using a logistic regression model with age, gender, and admixture adjustment. As
the main effect of SNP (rs334 HbS) had a minor allele frequency ofB0.04, the counts of samples homozygous for the minor allele were too small to have sufficient power in
additive or recessive models. Therefore, only the dominant model was examined and results are presented.
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the non-sickle trait group. The Wilcoxon two-sample P-value
was 0.19 for age and 0.003 for admixture; 53% of sickle trait
carriers were women as were 55% of the noncarriers
(P¼ 0.59). As admixture was associated with sickle trait
status, we adjusted for it to prevent confounding. Approxi-
mately 7–9% of African Americans possess one copy of
HbS.8,9 Our report evaluated prevalent dialysis patients and
similarly aged controls born in the southeastern United
States. Similar frequencies of HbS were observed in cases and
controls, although this sample consisted of middle-aged and
older participants. Our results neither support higher risk for
ESRD in HbS carriers nor a survival bias whereby HbS
carriers live longer than noncarriers. There is no a priori
evidence that heterozygous carriers of HbS manifest im-
proved survival and would therefore be more likely to survive
to initiate dialysis. We further note that the strong APOL1
genetic association initially observed with FSGS was easily
detectable in prevalent dialysis patients with all-cause ESRD
from this report.
In contrast to an earlier, smaller report, we conclude that
African Americans who have a single copy of the HbS gene
are not at increased risk for developing nondiabetic or
diabetic ESRD (or subclinical nephropathy), relative to
unaffected individuals. In addition, nephropathy risk variants
in APOL1 function independently from HbS when con-
tributing to nondiabetic ESRD.
MATERIALS AND METHODS
Patient populations
Diagnostic criteria for African American participants in on-going
genetic analyses of T2D- and non-T2D-associated ESRD at Wake
Forest School of Medicine have been reported.14,17,18 Briefly, self-
described African Americans born in North Carolina, South
Carolina, Georgia, Virginia, or Tennessee formed the study
population. Peripheral blood specimens for DNA extraction were
collected from unrelated prevalent dialysis patients who reportedly
had ESRD attributed to hypertension, glomerular disease, or T2D.
Cases were diagnosed as having hypertension-attributed ESRD by
virtue of high blood pressure preceding initiation of renal
replacement therapy with hypertensive target-organ damage (retino-
pathy or left ventricular hypertrophy) and low-level proteinuria
(p30mg/dl on urine dipstick, o0.5 g protein/24 h on timed urine
collection, or urine protein:creatinine ratio o0.5 g/g) or in the
absence of proteinuria measurements. In the presence of renal biopsy
evidence of a primary glomerular disease (e.g., FSGS), proteinuria
X0.5 g/24 h or X100mg/dl on urinalysis, nondiabetic subjects were
diagnosed as having chronic glomerular disease-associated ESRD.
T2D-associated ESRD was diagnosed in patients with diabetes
developing after the age of 25 years, with renal histological evidence
of diabetic nephropathy or diabetes durations X5 years before
initiating renal replacement therapy in the presence of diabetic
retinopathy and/or proteinuria 4500mg/24 h, or with 45 years
diabetes duration before ESRD in the absence of other known causes
of kidney disease. Individuals with cystic renal diseases, hereditary
nephritis, or urological causes of ESRD were excluded.
The control group was recruited from the same geographical
region as ESRD cases. Nondiabetic controls included 780 individuals
without nephropathy identified at primary care medicine clinics,
community health fairs, and community screenings. Because
of their low risk for developing nephropathy, serum creatinine
concentrations were not uniformly measured in nondiabetic
controls. However, in a subset of 602 of these controls, 98.4%
were found to have serum creatinine concentrations p1.5mg/dl in
men and p1.3mg/dl in women (the 16 controls with elevated
serum creatinine concentrations were excluded from analysis).
Additional controls with T2D included 413 African American-
Diabetes Heart Study participants, all with serum creatinine
concentrations p1.5mg/dl in men and p1.3mg/dl in women,
and a spot urine albumin:creatinine ratio o30mg/g.19 Although
a small number of controls may have chronic kidney disease,
these criteria make it unlikely that many had estimated
glomerular filtration rates below 60ml/min. All cases and controls
provided written informed consent, and the study was approved by
the Institutional Review Board at the Wake Forest School of
Medicine.
Genotyping
DNA extraction from whole blood was performed using the
PureGene system (Gentra Systems, Minneapolis, MN). The HbS
single-nucleotide polymorphism (rs334) was genotyped using the
iPLEX Sequenom MassARRAY platform (San Diego, CA). Seventy
diallelic ancestry informative markers were genotyped to determine
whether population substructure biased our results.20 The 44 Yoruba
(YRI), 39 European American controls, 1177 African American
controls, and 2081 African American ESRD samples were genotyped
using Custom Genotyping Services (Illumina, San Diego, CA) or
Sequenom MassArray. Genotyping efficiency was498.4%, and 104
blind duplicates were included to ensure genotyping accuracy.
Statistical analyses
HbS allele frequency differences between the case and control groups
were analyzed using logistic regression multivariable models
adjusting for admixture, age, and gender under a dominant genetic
model. SNPGWA version 4.0 was used to calculate genotypic
association adjusted for African ancestry proportions. FRAPPE
(Frequentist Estimation of Individual Ancestry Proportion) was
used to calculate African ancestry proportions in the case and
control population.20
An interaction term between HbS and (a) MYH9 risk variants or
(b) APOL1 risk variants was fitted in the logistic regression model to
assess whether the OR of HbS varied significantly with risk status for
MYH9 or APOL1. MYH9 ‘risk’ was defined as homozygosity for the
E1 haplotype.12–14 APOL1 ‘risk’ was defined as two copies of the G1
or G2 risk alleles.10 To improve power to detect small-effect
gene–gene interactions, case-only analyses were performed to
evaluate potential interactions between HbS andMYH9 or APOL1.21
As APOL1 and MYH9 both reside on chromosome 22, a
chromosome different from HbS, the assumption of independence
between the genes holds using this approach.
P-values, ORs, and 95% CIs were calculated to assess the
relationship between HbS and ESRD, as well as interactions between
HbS and the chromosome 22 nephropathy risk variants. The
interaction analyses were performed using SAS software (version
8.2; SAS Institute, Cary, NC), and hypothesis tests were two-sided
and considered statistically significant at Po0.05.
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